Tiedemann Wealth Management LLC acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,196 shares of the medical instruments supplier’s stock, valued at approximately $207,000.

A number of other large investors have also added to or reduced their stakes in WST. Acrospire Investment Management LLC bought a new stake in West Pharmaceutical Services in the second quarter valued at approximately $113,000. Citigroup Inc. raised its stake in West Pharmaceutical Services by 95.1% in the second quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 765 shares during the period. Wolverine Trading LLC bought a new stake in West Pharmaceutical Services in the second quarter valued at approximately $200,000. Nomura Holdings Inc. bought a new stake in West Pharmaceutical Services in the second quarter valued at approximately $201,000. Finally, Grandfield & Dodd LLC bought a new stake in West Pharmaceutical Services in the third quarter valued at approximately $201,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

WST has been the topic of several research analyst reports. Jefferies Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $115.00 in a research note on Friday, September 15th. Bank of America lowered West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective on the stock. in a research note on Tuesday, October 17th. Wells Fargo & Company upped their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. Finally, Stephens initiated coverage on West Pharmaceutical Services in a research note on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services currently has an average rating of “Hold” and a consensus price target of $106.00.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) traded down $0.78 during midday trading on Friday, hitting $99.11. The stock had a trading volume of 288,935 shares, compared to its average volume of 276,426. The company has a market capitalization of $7,420.10, a price-to-earnings ratio of 43.07, a P/E/G ratio of 2.13 and a beta of 1.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. West Pharmaceutical Services, Inc. has a one year low of $77.97 and a one year high of $103.36.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.14. The company had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.53 earnings per share. research analysts predict that West Pharmaceutical Services, Inc. will post 2.76 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/02/tiedemann-wealth-management-llc-acquires-new-position-in-west-pharmaceutical-services-inc-wst.html.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.